Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 61.51
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA... 
Via Benzinga
Exposures Product Safety
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling. 
Via Benzinga

Performance

More News

Read More
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
Via Benzinga
Exposures Product Safety
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
Via Benzinga
Why Is Biogen Stock Trading Lower On Tuesday?
Via Benzinga
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
Via Benzinga
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
Via Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
Via Benzinga
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
Via Benzinga
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Via Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Via Benzinga
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Via Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Via Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Via Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Via Benzinga
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Via The Motley Fool
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Via MarketBeat
Exposures Product Safety
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
Via Benzinga
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
Via Benzinga
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories
Via Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Via Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
Via Benzinga
Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
Via Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Via Benzinga

Frequently Asked Questions

Is Eisai Ltd ADR publicly traded?
Yes, Eisai Ltd ADR is publicly traded.
What exchange does Eisai Ltd ADR trade on?
Eisai Ltd ADR trades on the OTC Traded
What is the ticker symbol for Eisai Ltd ADR?
The ticker symbol for Eisai Ltd ADR is ESALY on the OTC Traded
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.